NCT03658655CompletedEarly Phase 1
Open, One-arm, Single-center Clinical Study to Evaluate the Efficacy and Safety of Stem Cells From Human Exfoliated Teeth in the Treatment of Type 2 Diabetes
CAR-T (Shanghai) Biotechnology Co., Ltd.1 site in 1 country24 target enrollmentStarted: June 1, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Total daily insulin
Study Overview
Brief Summary
To evaluate the safety and efficacy of Stem Cells From Human Exfoliated Teethtransplantation in patients with type 2 diabetes to provides scientific basis for further clinical studies to verify the safety and efficacy of type 2 diabetes.On the basis of maintaining the original treatment, intravenous drip of Stem Cells From Human Exfoliated Teeth.
Detailed Description
Basic treatment:
The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).
Stem cell therapy:
Dosage: Stem Cells From Human Exfoliated Teeth were calculated at 0.1IU/kg body weight .
Course of treatment: 3 times, respectively at the time of enrollment, 1 week after enrollment and 4 weeks after enrollment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 45 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Be able to understand the purpose of clinical trial, voluntarily participate in and sign the informed consent;
- •Patients with type 2 diabetes WHO were clearly diagnosed according to WHO diagnostic criteria with a course of over 5 years;
- •Fasting blood glucose (FPG) was still 7.5-12.0mmol/L and hemoglobin a1c (HbAlc) was still 7.0-10.0% after insulin treatment or combined with oral hypoglycemic drugs; Among them, insulin has been treated for 1 year, and the number of subcutaneous injection is 2 times or more in the last 3 months, and the type and dose of oral hypoglycemic drugs (including metformin only, antinylglycosidase inhibitors or insulin prolactin) have been stable and decreased for 3 months.
- •Age 45 to 65 years male and female;
- •Body mass index (BMI) between 20 and 30kg/m2;
- •Male or Female subjects of childbearing age shall voluntarily take birth control measures from the screening date to the end of the follow-up;Urine pregnancy test was negative during screening of women of reproductive age, and serum pregnancy test was performed when necessary to exclude pregnancy.
Exclusion Criteria
- •Patients with type 1 diabetes, gestational diabetes or other special type of diabetes;
- •All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the first month;
- •Patients who had received other stem cell therapy before screening;
- •Patients with poorly controlled hypertension had a blood pressure of 160/100mmHg during screening;
- •Screening those who had taken thiazolidinedione, DDP-IV inhibitors and GLP-1 drugs within the first 3 months;
- •Insulin therapy was used for less than 1 year before screening, and only subcutaneous injection was performed daily for nearly 3 months; One dose insulin;
- •Patients with pancreatic diseases, including those with acute and chronic pancreatitis and pancreatic tumors;
- •Those with other malignant or suspected tumor tendencies;Or in active phase of infection (including hepatitis b or HCV);Immunodeficiency virus (HIV) positive patients;
- •Patients suffering from other serious systemic diseases (such as cardiovascular system, respiratory system, digestive system, nervous system, endocrine system, genitourinary system, immune system and blood system);
- •Patients with abnormal liver and kidney function, such as serum bilirubin TBIL exceeding 1.5 times of the normal upper limit, glutamate AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine Cr exceeding 1.2 times of the normal upper limit;
- •Being treated with systemic sex hormones (glucocorticoids), immunosuppressive or cytotoxic agents;
- •Disabled person (blind, deaf, dumb, mentally handicapped, or physically disabled) as prescribed by law, a pregnant and lactating woman;People with mental illness;Patients who have a history of drug abuse or alcohol dependence within 5 years;
- •Patients with contraindications or allergies treated in this study;
- •Subjects who participated in other clinical studies within the last three months.
Outcomes
Primary Outcomes
Total daily insulin
Time Frame: 1 week
After treatment total daily insulin dose changes
Secondary Outcomes
- HbAlc(1 week)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Early Phase 1
Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet FunctionType1diabetesNCT03912480CAR-T (Shanghai) Biotechnology Co., Ltd.24
Unknown
Not Applicable
Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of DepressionDepressionNCT05127369CAR-T (Shanghai) Biotechnology Co., Ltd.48
Completed
Phase 1
Human Placental-Derived Stem Cell TransplantationMucopolysaccharidosis IMucopolysaccharidosis VINiemann-Pick DiseaseBatten DiseaseMetachromatic LeukodystrophyWolman DiseaseKrabbe's DiseaseGaucher's DiseaseDiamond-Blackfan AnemiaAmegakaryocytic ThrombocytopeniaAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaMyelodysplastic SyndromeSevere Aplastic AnemiaFucosidosisAdrenoleukodystrophyNCT01586455New York Medical College43
Unknown
Early Phase 1
Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee OsteoarthritisKnee OsteoarthritisNCT04130100CAR-T (Shanghai) Biotechnology Co., Ltd.60
Recruiting
Phase 1
Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry EyeDry Eye SyndromesNCT06543667Iran University of Medical Sciences30